MICU Vicuron Pharmaceuticals (MM)

Wolf Haldenstein Adler Freeman and Herz LLP Commences Class Action Lawsuit on Behalf of Vicuron Pharmaceuticals, Inc. Shareholders NEW YORK, July 21 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP filed a class action lawsuit in the United States District Court for the Eastern District of Pennsylvania, on behalf of all persons who purchased the common stock of Vicuron Pharmaceuticals, Inc. ("Vicuron" or the "Company") (NASDAQ:MICU) between January 6, 2003 and May 24, 2004, inclusive, (the "Class Period") against defendants Vicuron and certain officers of the Company. The case name is Staton v. Vicuron Pharmaceuticals, Inc., et al. A copy of the complaint filed in this action is available from the Court, or can be viewed on the Wolf Haldenstein Adler Freeman & Herz LLP website at http://www.whafh.com/cases/vicuron.htm. The complaint alleges that defendants violated the federal securities laws by issuing materially false and misleading statements throughout the Class Period that had the effect of artificially inflating the market price of the Company's securities. The complaint specifically alleges that during the Class Period, defendants artificially inflated the price of Vicuron stock by concealing critical material information regarding the details of both the safety and efficacy of Anidulafungin, the Company's lead product candidate. Defendants concealed key adverse information regarding the development and commercialization of Anidulafungin, raising serious concerns for the very approval of the drug for the treatment of esophageal candidiasis and other selected indications. The partial disclosure of the contents of the FDA letter on Monday, May 24, 2004, detailing the failure of Vicuron to supply data necessary to support its very claim for the use of Anidulafungin for the treatment of esophageal candidiasis caused Vicuron shares to plummet $8.86, to $13.04, for a loss of over 40% from the previous trading day and over 45% from its Class Period high of $23.90, on volume of over 15 million shares, causing millions of dollars in damages to members of the Class. If you purchased Vicuron common stock during the Class Period, you may request that the Court appoint you as lead plaintiff by August 16, 2004. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Wolf Haldenstein, or other counsel of your choice, to serve as your counsel in this action. Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has approximately 60 attorneys in various practice areas; and offices in Chicago, New York City, San Diego, and West Palm Beach. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation. If you wish to discuss this action or have any questions, please contact Wolf Haldenstein Adler Freeman & Herz LLP at 270 Madison Avenue, New York, New York 10016, by telephone at (800) 575-0735 (Fred Taylor Isquith, Esq., Christopher Hinton, Esq., or Derek Behnke), via e-mail at or visit our website at http://www.whafh.com/. All e-mail correspondence should make reference to Vicuron. DATASOURCE: Wolf Haldenstein Adler Freeman & Herz LLP CONTACT: Fred Taylor Isquith, Esq., Christopher Hinton, Esq., or Derek Behnke, all of Wolf Haldenstein Adler Freeman & Herz LLP, 1-800-575-0735, or Web site: http://www.whafh.com/

Copyright